216 results on '"Hobbs FD Richard"'
Search Results
2. Ivermectin for COVID-19 in adults in the community (PRINCIPLE): An open, randomised, controlled, adaptive platform trial of short- and longer-term outcomes
- Author
-
Hayward, Gail, Yu, Ly-Mee, Little, Paul, Gbinigie, Oghenekome, Shanyinde, Milensu, Harris, Victoria, Dorward, Jienchi, Saville, Benjamin R., Berry, Nicholas, Evans, Philip H., Thomas, Nicholas P.B., Patel, Mahendra G., Richards, Duncan, Hecke, Oliver V., Detry, Michelle A., Saunders, Christina, Fitzgerald, Mark, Robinson, Jared, Latimer-Bell, Charlotte, Allen, Julie, Ogburn, Emma, Grabey, Jenna, de Lusignan, Simon, Hobbs, FD Richard, and Butler, Christopher C.
- Published
- 2024
- Full Text
- View/download PDF
3. Protocol for Past BP: a randomised controlled trial of different blood pressure targets for people with a history of stroke of transient ischaemic attack (TIA) in primary care
- Author
-
Greenfield Sheila, Martin Una, Jowett Sue, Virdee Satnam, Taylor Clare, Betts Jonathan, Campbell Sarah, McManus Richard, Mant Jonathan, Fletcher Kate, Ford Gary, Freemantle Nick, and Hobbs FD Richard
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background Blood pressure (BP) lowering in people who have had a stroke or transient ischaemic attack (TIA) leads to reduced risk of further stroke. However, it is not clear what the target BP should be, since intensification of therapy may lead to additional adverse effects. PAST BP will determine whether more intensive BP targets can be achieved in a primary care setting, and whether more intensive therapy is associated with adverse effects on quality of life. Methods/Design This is a randomised controlled trial (RCT) in patients with a past history of stroke or TIA. Patients will be randomised to two groups and will either have their blood pressure (BP) lowered intensively to a target of 130 mmHg systolic, (or by 10 mmHg if the baseline systolic pressure is between 125 and 140 mmHg) compared to a standard group where the BP will be reduced to a target of 140 mmHg systolic. Patients will be managed by their practice at 1-3 month intervals depending on level of BP and followed-up by the research team at six monthly intervals for 12 months. 610 patients will be recruited from approximately 50 general practices. The following exclusion criteria will be applied: systolic BP The primary outcome will be change in systolic BP over twelve months. Secondary outcomes include quality of life, adverse events and cardiovascular events. In-depth interviews with 30 patients and 20 health care practitioners will be undertaken to investigate patient and healthcare professionals understanding and views of BP management. Discussion The results of this trial will inform whether intensive blood pressure targets can be achieved in people who have had a stroke or TIA in primary care, and help determine whether or not further research is required before recommending such targets for this population. Trial Registration ISRCTN29062286
- Published
- 2010
- Full Text
- View/download PDF
4. Protocol for a randomised controlled trial of telemonitoring and self-management in the control of hypertension: Telemonitoring and self-management in hypertension. [ISRCTN17585681]
- Author
-
Little Paul, Jones Miren I, Bryan Stirling, Greenfield Sheila, Holder Roger, Mant Jonathan, Bray Emma P, McManus Richard J, Williams Bryan, and Hobbs FD Richard
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background Controlling blood pressure with drugs is a key aspect of cardiovascular disease prevention, but until recently has been the sole preserve of health professionals. Self-management of hypertension is an under researched area in which potential benefits for both patients and professionals are great. Methods and design The telemonitoring and self-management in hypertension trial (TASMINH2) will be a primary care based randomised controlled trial with embedded economic and qualitative analyses in order to evaluate the costs and effects of increasing patient involvement in blood pressure management, specifically with respect to home monitoring and self titration of antihypertensive medication compared to usual care. Provision of remote monitoring results to participating practices will ensure that practice staff are able to engage with self management and provide assistance where required. 478 patients will be recruited from general practices in the West Midlands, which is sufficient to detect clinically significant differences in systolic blood pressure between self-management and usual care of 5 mmHg with 90% power. Patients will be excluded if they demonstrate an inability to self monitor, their blood pressure is below 140/90 or above 200/100, they are on three or more antihypertensive medications, have a terminal disease or their blood pressure is not managed by their general practitioner. The primary end point is change in mean systolic blood pressure (mmHg) between baseline and each follow up point (6 months and 12 months). Secondary outcomes will include change in mean diastolic blood pressure, costs, adverse events, health behaviours, illness perceptions, beliefs about medication, medication compliance and anxiety. Modelling will evaluate the impact of costs and effects on a system wide basis. The qualitative analysis will draw upon the views of users, informal carers and professionals regarding the acceptability of self-management and prerequisites for future widespread implementation should the trial show this approach to be efficacious. Discussion The TASMINH2 trial will provide important new evidence regarding the costs and effects of self monitoring with telemonitoring in a representative primary care hypertensive population. Trial Registration ISRCTN17585681
- Published
- 2009
- Full Text
- View/download PDF
5. Heart failure guidelines and prescribing in primary care across Europe
- Author
-
Hobbs FD Richard, Swedberg Karl, van Gilst Wiek H, Sturm Heidrun B, and Haaijer-Ruskamp Flora M
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Major international differences in heart failure treatment have been repeatedly described, but the reasons for these differences remain unclear. National guideline recommendations might be a relevant factor. This study, therefore, explored variation of heart failure guideline recommendations in Europe. Methods Treatment recommendations of 14 national guidelines published after 1994 were analyzed in relation to the heart failure treatment guideline of the European Society of Cardiology. To test potential relations between recommendations and prescribing, national prescribing patterns as obtained by a European study in primary care (IMPROVEMENT-HF) were related to selected recommendations in those countries. Results Besides the 14 national guidelines used by primary care physicians in the countries contacted, the European guideline was used in four countries, and separate guidelines for specialists and primary care were available in another four countries. Two countries indicated that no guideline was used up to 2000. Comprehensiveness of the guidelines varied with respect to length, literature included and evidence ratings. Relevant differences in treatment recommendations were seen only in drug classes where evidence had changed recently (β-blockers and spironolactone). The relation between recommendation and prescribing for selected recommendations was inconsistent among countries. Conclusion Differences in guideline recommendations are not sufficient to explain variation of prescribing among countries, thus other factors must be considered.
- Published
- 2005
- Full Text
- View/download PDF
6. Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study
- Author
-
Nicholson, Brian D, Oke, Jason, Virdee, Pradeep S, Harris, Dean A, O'Doherty, Catherine, Park, John ES, Hamady, Zaed, Sehgal, Vinay, Millar, Andrew, Medley, Louise, Tonner, Sharon, Vargova, Monika, Engonidou, Lazarina, Riahi, Kaveh, Luan, Ying, Hiom, Sara, Kumar, Harpal, Nandani, Harit, Kurtzman, Kathryn N, Yu, Ly-Mee, Freestone, Clare, Pearson, Sarah, Hobbs, FD Richard, Perera, Rafael, and Middleton, Mark R
- Published
- 2023
- Full Text
- View/download PDF
7. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial fibrillation in an elderly primary care population [ISRCTN89345269]
- Author
-
Fletcher Kate, Banting Miriam, Murray Ellen, Lip Gregory YH, Fitzmaurice David, Hobbs FD Richard, Richards Suzanne H, Mant Jonathan WF, Rahman Joy, Allan Teresa, Raftery James, and Bryan Stirling
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background Atrial fibrillation (AF) is an important independent risk factor for stroke. Randomised controlled trials have shown that this risk can be reduced substantially by treatment with warfarin or more modestly by treatment with aspirin. Existing trial data for the effectiveness of warfarin are drawn largely from studies in selected secondary care populations that under-represent the elderly. The Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA) study will provide evidence of the risks and benefits of warfarin versus aspirin for the prevention of stroke for older people with AF in a primary care setting. Study design A randomised controlled trial where older patients with AF are randomised to receive adjusted dose warfarin or aspirin. Patients will be followed up at three months post-randomisation, then at six monthly intervals there after for an average of three years by their general practitioner. Patients will also receive an annual health questionnaire. 1240 patients will be recruited from over 200 practices in England. Patients must be aged 75 years or over and have AF. Patients will be excluded if they have a history of any of the following conditions: rheumatic heart disease; major non-traumatic haemorrhage; intra-cranial haemorrhage; oesophageal varices; active endoscopically proven peptic ulcer disease; allergic hypersensitivity to warfarin or aspirin; or terminal illness. Patients will also be excluded if the GP considers that there are clinical reasons to treat a patient with warfarin in preference to aspirin (or vice versa). The primary end-point is fatal or non-fatal disabling stroke (ischaemic or haemorrhagic) or significant arterial embolism. Secondary outcomes include major extra-cranial haemorrhage, death (all cause, vascular), hospital admissions (all cause, vascular), cognition, quality of life, disability and compliance with study medication.
- Published
- 2003
- Full Text
- View/download PDF
8. Prioritising primary care patients with unexpected weight loss for cancer investigation : diagnostic accuracy study
- Author
-
Nicholson, Brian D, Aveyard, Paul, Price, Sarah J, Hobbs, FD Richard, Koshiaris, Constantinos, and Hamilton, Willie
- Published
- 2020
9. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
- Author
-
Yu, Ly-Mee, Bafadhel, Mona, Dorward, Jienchi, Hayward, Gail, Saville, Benjamin R, Gbinigie, Oghenekome, van Hecke, Oliver, Ogburn, Emma, Evans, Philip H, Thomas, Nicholas PB, Patel, Mahendra G, Richards, Duncan, Berry, Nicholas, Detry, Michelle A, Saunders, Christina T, Fitzgerald, Mark, Harris, Victoria, Shanyinde, Milensu, de Lusignan, Simon, Andersson, Monique I, Barnes, Peter J, Russell, Richard EK, Nicolau, Dan V, Ramakrishnan, Sanjay, Hobbs, FD Richard, Butler, Christopher C, Van Hecke, Oliver, Thomas, Nicholas P B, Saunders, Christina, Russell, Richard E K, Nicolau, Dan V, Jr, and Hobbs, F D Richard
- Published
- 2021
- Full Text
- View/download PDF
10. The Association between Blood Test Trends and Undiagnosed Cancer: A Systematic Review and Critical Appraisal.
- Author
-
Virdee, Pradeep S., Collins, Kiana K., Friedemann Smith, Claire, Yang, Xin, Zhu, Sufen, Roberts, Sophie E., Roberts, Nia, Oke, Jason L., Bankhead, Clare, Perera, Rafael, Hobbs, FD Richard, and Nicholson, Brian D.
- Subjects
TUMOR risk factors ,RISK assessment ,MEDICAL information storage & retrieval systems ,BLOOD testing ,RESEARCH funding ,PRIMARY health care ,HEMOGLOBINS ,COLORECTAL cancer ,DESCRIPTIVE statistics ,SYSTEMATIC reviews ,MEDLINE ,BLOOD sugar ,PANCREATIC tumors ,C-reactive protein ,FASTING - Abstract
Simple Summary: Blood tests are commonly requested by doctors.Blood tests are done for many reasons and invesitgating symptoms or monitoring existing conditions are just examples. For instance, blood tests can also be done as part of a routine health checkup to investigate symptoms or monitor existing conditions. For instance, blood tests can also be done as part of a routine health checkup. Some clinical guidelines for doctors include recommendations to investigate for cancer if a blood test indicates results that are lower or higher than normal levels. These recommendations are only helpful for a small number of cancers, such as bowel or pancreatic cancers. A patient can have repeated blood tests, allowing doctors to monitor how blood test results change over time. These changes over time are referred to as 'trends' and may provide doctors with more information than the results of a single blood test. For example, noting a small drop in a steady trend could be more useful than waiting for the blood test to drop below a normal level. Until now, there has been no research regarding whether blood test trends can identify patients who should be investigated for cancer. We aimed to assess this possibility in this research project. Clinical guidelines include monitoring blood test abnormalities to identify patients at increased risk of undiagnosed cancer. Noting blood test changes over time may improve cancer risk stratification by considering a patient's individual baseline and important changes within the normal range. We aimed to review the published literature to understand the association between blood test trends and undiagnosed cancer. MEDLINE and EMBASE were searched until 15 May 2023 for studies assessing the association between blood test trends and undiagnosed cancer. We used descriptive summaries and narratively synthesised studies. We included 29 articles. Common blood tests were haemoglobin (24%, n = 7), C-reactive protein (17%, n = 5), and fasting blood glucose (17%, n = 5), and common cancers were pancreatic (29%, n = 8) and colorectal (17%, n = 5). Of the 30 blood tests studied, an increasing trend in eight (27%) was associated with eight cancer types, and a decreasing trend in 17 (57%) with 10 cancer types. No association was reported between trends in 11 (37%) tests and breast, bile duct, glioma, haematological combined, liver, prostate, or thyroid cancers. Our review highlights trends in blood tests that could facilitate the identification of individuals at increased risk of undiagnosed cancer. For most possible combinations of tests and cancers, there was limited or no evidence. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. The association between blood pressure control and Coronavirus Disease 2019 outcomes in 45,418 symptomatic patients with hypertension: An observational cohort study
- Author
-
Sheppard, James P., Nicholson, Brian D., Lee, Joseph, McGagh, Dylan, Sherlock, Julian, Koshiaris, Constantinos, Oke, Jason, Jones, Nicholas R, Hinton, William, Armitage, Laura, Van Hecke, Oliver, Lay-Flurrie, Sarah, Bankhead, Clare R., Liyanage, Harshana, Williams, John, Ferreira, Filipa, Feher, Michael D., Ashworth, Andrew J., Joy, Mark P., de Lusignan, Simon, and Hobbs, FD Richard
- Published
- 2020
- Full Text
- View/download PDF
12. Influenza and Respiratory Virus Surveillance, Vaccine Uptake, and Effectiveness at a Time of Cocirculating COVID-19: Protocol for the English Primary Care Sentinel System for 2020-2021
- Author
-
de Lusignan, Simon, Lopez Bernal, Jamie, Byford, Rachel, Amirthalingam, Gayatri, Ferreira, Filipa, Akinyemi, Oluwafunmi, Andrews, Nick, Campbell, Helen, Dabrera, Gavin, Deeks, Alexandra, Elliot, Alex J, Krajenbrink, Else, Liyanage, Harshana, McGagh, Dylan, Okusi, Cecilia, Parimalanathan, Vaishnavi, Ramsay, Mary, Smith, Gillian, Tripathy, Manasa, Williams, John, Victor, William, Zambon, Maria, Howsam, Gary, Nicholson, Brian David, Tzortziou Brown, Victoria, Butler, Christopher C, Joy, Mark, and Hobbs, FD Richard
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
BackgroundThe Oxford–Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) and Public Health England (PHE) are commencing their 54th season of collaboration at a time when SARS-CoV-2 infections are likely to be cocirculating with the usual winter infections. ObjectiveThe aim of this study is to conduct surveillance of influenza and other monitored respiratory conditions and to report on vaccine uptake and effectiveness using nationally representative surveillance data extracted from primary care computerized medical records systems. We also aim to have general practices collect virology and serology specimens and to participate in trials and other interventional research. MethodsThe RCGP RSC network comprises over 1700 general practices in England and Wales. We will extract pseudonymized data twice weekly and are migrating to a system of daily extracts. First, we will collect pseudonymized, routine, coded clinical data for the surveillance of monitored and unexpected conditions; data on vaccine exposure and adverse events of interest; and data on approved research study outcomes. Second, we will provide dashboards to give general practices feedback about levels of care and data quality, as compared to other network practices. We will focus on collecting data on influenza-like illness, upper and lower respiratory tract infections, and suspected COVID-19. Third, approximately 300 practices will participate in the 2020-2021 virology and serology surveillance; this will include responsive surveillance and long-term follow-up of previous SARS-CoV-2 infections. Fourth, member practices will be able to recruit volunteer patients to trials, including early interventions to improve COVID-19 outcomes and point-of-care testing. Lastly, the legal basis for our surveillance with PHE is Regulation 3 of the Health Service (Control of Patient Information) Regulations 2002; other studies require appropriate ethical approval. ResultsThe RCGP RSC network has tripled in size; there were previously 100 virology practices and 500 practices overall in the network and we now have 322 and 1724, respectively. The Oxford–RCGP Clinical Informatics Digital Hub (ORCHID) secure networks enable the daily analysis of the extended network; currently, 1076 practices are uploaded. We are implementing a central swab distribution system for patients self-swabbing at home in addition to in-practice sampling. We have converted all our primary care coding to Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT) coding. Throughout spring and summer 2020, the network has continued to collect specimens in preparation for the winter or for any second wave of COVID-19 cases. We have collected 5404 swabs and detected 623 cases of COVID-19 through extended virological sampling, and 19,341 samples have been collected for serology. This shows our preparedness for the winter season. ConclusionsThe COVID-19 pandemic has been associated with a groundswell of general practices joining our network. It has also created a permissive environment in which we have developed the capacity and capability of the national primary care surveillance systems and our unique public health institute, the RCGP and University of Oxford collaboration.
- Published
- 2021
- Full Text
- View/download PDF
13. The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: Protocol to Develop Extended COVID-19 Surveillance and Trial Platforms
- Author
-
de Lusignan, Simon, Jones, Nicholas, Dorward, Jienchi, Byford, Rachel, Liyanage, Harshana, Briggs, John, Ferreira, Filipa, Akinyemi, Oluwafunmi, Amirthalingam, Gayatri, Bates, Chris, Lopez Bernal, Jamie, Dabrera, Gavin, Eavis, Alex, Elliot, Alex J, Feher, Michael, Krajenbrink, Else, Hoang, Uy, Howsam, Gary, Leach, Jonathan, Okusi, Cecilia, Nicholson, Brian, Nieri, Philip, Sherlock, Julian, Smith, Gillian, Thomas, Mark, Thomas, Nicholas, Tripathy, Manasa, Victor, William, Williams, John, Wood, Ian, Zambon, Maria, Parry, John, O’Hanlon, Shaun, Joy, Mark, Butler, Chris, Marshall, Martin, and Hobbs, FD Richard
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
BackgroundRoutinely recorded primary care data have been used for many years by sentinel networks for surveillance. More recently, real world data have been used for a wider range of research projects to support rapid, inexpensive clinical trials. Because the partial national lockdown in the United Kingdom due to the coronavirus disease (COVID-19) pandemic has resulted in decreasing community disease incidence, much larger numbers of general practices are needed to deliver effective COVID-19 surveillance and contribute to in-pandemic clinical trials. ObjectiveThe aim of this protocol is to describe the rapid design and development of the Oxford Royal College of General Practitioners Clinical Informatics Digital Hub (ORCHID) and its first two platforms. The Surveillance Platform will provide extended primary care surveillance, while the Trials Platform is a streamlined clinical trials platform that will be integrated into routine primary care practice. MethodsWe will apply the FAIR (Findable, Accessible, Interoperable, and Reusable) metadata principles to a new, integrated digital health hub that will extract routinely collected general practice electronic health data for use in clinical trials and provide enhanced communicable disease surveillance. The hub will be findable through membership in Health Data Research UK and European metadata repositories. Accessibility through an online application system will provide access to study-ready data sets or developed custom data sets. Interoperability will be facilitated by fixed linkage to other key sources such as Hospital Episodes Statistics and the Office of National Statistics using pseudonymized data. All semantic descriptors (ie, ontologies) and code used for analysis will be made available to accelerate analyses. We will also make data available using common data models, starting with the US Food and Drug Administration Sentinel and Observational Medical Outcomes Partnership approaches, to facilitate international studies. The Surveillance Platform will provide access to data for health protection and promotion work as authorized through agreements between Oxford, the Royal College of General Practitioners, and Public Health England. All studies using the Trials Platform will go through appropriate ethical and other regulatory approval processes. ResultsThe hub will be a bottom-up, professionally led network that will provide benefits for member practices, our health service, and the population served. Data will only be used for SQUIRE (surveillance, quality improvement, research, and education) purposes. We have already received positive responses from practices, and the number of practices in the network has doubled to over 1150 since February 2020. COVID-19 surveillance has resulted in tripling of the number of virology sites to 293 (target 300), which has aided the collection of the largest ever weekly total of surveillance swabs in the United Kingdom as well as over 3000 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology samples. Practices are recruiting to the PRINCIPLE (Platform Randomised trial of INterventions against COVID-19 In older PeopLE) trial, and these participants will be followed up through ORCHID. These initial outputs demonstrate the feasibility of ORCHID to provide an extended national digital health hub. ConclusionsORCHID will provide equitable and innovative use of big data through a professionally led national primary care network and the application of FAIR principles. The secure data hub will host routinely collected general practice data linked to other key health care repositories for clinical trials and support enhanced in situ surveillance without always requiring large volume data extracts. ORCHID will support rapid data extraction, analysis, and dissemination with the aim of improving future research and development in general practice to positively impact patient care. International Registered Report Identifier (IRRID)DERR1-10.2196/19773
- Published
- 2020
- Full Text
- View/download PDF
14. Lessons from the English primary care sentinel network's response to the COVID-19 pandemic
- Author
-
de Lusignan, Simon, Hobbs, FD Richard, and Sheikh, Aziz
- Published
- 2024
- Full Text
- View/download PDF
15. An internet-based intervention with brief nurse support to manage obesity in primary care (POWeR+): a pragmatic, parallel-group, randomised controlled trial
- Author
-
Little, Paul, Stuart, Beth, Hobbs, FD Richard, Kelly, Jo, Smith, Emily R, Bradbury, Katherine J, Hughes, Stephanie, Smith, Peter W F, Moore, Michael V, Lean, Mike E J, Margetts, Barrie M, Byrne, Chris D, Griffin, Simon, Davoudianfar, Mina, Hooper, Julie, Yao, Guiqing, Zhu, Shihua, Raftery, James, and Yardley, Lucy
- Published
- 2016
- Full Text
- View/download PDF
16. Predicting the risk of acute kidney injury in primary care: derivation and validation of STRATIFY-AKI.
- Author
-
Koshiaris, Constantinos, Archer, Lucinda, Lay-Flurrie, Sarah, Snell, Kym IE, Riley, Richard D, Stevens, Richard, Banerjee, Amitava, Usher-Smith, Juliet A, Clegg, Andrew, Payne, Rupert A, Ogden, Margaret, Hobbs, FD Richard, McManus, Richard J, and Sheppard, James P
- Subjects
ACUTE kidney failure ,PRIMARY care ,BLOOD pressure measurement ,MEDICAL research ,DRUG side effects - Abstract
Background: Antihypertensives reduce the risk of cardiovascular disease but are also associated with harms including acute kidney injury (AKI). Few data exist to guide clinical decision making regarding these risks. Aim: To develop a prediction model estimating the risk of AKI in people potentially indicated for antihypertensive treatment. Design and setting: Observational cohort study using routine primary care data from the Clinical Practice Research Datalink (CPRD) in England. Method: People aged ≥40 years, with at least one blood pressure measurement between 130 mmHg and 179 mmHg were included. Outcomes were admission to hospital or death with AKI within 1, 5, and 10 years. The model was derived with data from CPRD GOLD (n = 1 772 618), using a Fine–Gray competing risks approach, with subsequent recalibration using pseudo-values. External validation used data from CPRD Aurum (n = 3 805 322). Results: The mean age of participants was 59.4 years and 52% were female. The final model consisted of 27 predictors and showed good discrimination at 1, 5, and 10 years (C-statistic for 10-year risk 0.821, 95% confidence interval [CI] = 0.818 to 0.823). There was some overprediction at the highest predicted probabilities (ratio of observed to expected event probability for 10-year risk 0.633, 95% CI = 0.621 to 0.645), affecting patients with the highest risk. Most patients (>95%) had a low 1- to 5-year risk of AKI, and at 10 years only 0.1% of the population had a high AKI and low CVD risk. Conclusion: This clinical prediction model enables GPs to accurately identify patients at high risk of AKI, which will aid treatment decisions. As the vast majority of patients were at low risk, such a model may provide useful reassurance that most antihypertensive treatment is safe and appropriate while flagging the few for whom this is not the case. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. Development of a modified Cambridge Multimorbidity Score for use with SNOMED CT: an observational English primary care sentinel network study.
- Author
-
Tsang, Ruby SM, Joy, Mark, Whitaker, Heather, Sheppard, James P, Williams, John, Sherlock, Julian, Mayor, Nikhil, Meza-Torres, Bernardo, Button, Elizabeth, Williams, Alice J, Kar, Debasish, Delanerolle, Gayathri, McManus, Richard, Hobbs, FD Richard, and de Lusignan, Simon
- Subjects
SYSTEMATIZED Nomenclature of Medicine ,APACHE (Disease classification system) ,COMORBIDITY ,PRIMARY care ,PROPORTIONAL hazards models ,ELECTRONIC health records ,AKAIKE information criterion - Abstract
Background: People with multiple health conditions are more likely to have poorer health outcomes and greater care and service needs; a reliable measure of multimorbidity would inform management strategies and resource allocation. Aim: To develop and validate a modified version of the Cambridge Multimorbidity Score in an extended age range, using clinical terms that are routinely used in electronic health records across the world (Systematized Nomenclature of Medicine — Clinical Terms, SNOMED CT). Design and setting: Observational study using diagnosis and prescriptions data from an English primary care sentinel surveillance network between 2014 and 2019. Method: In this study new variables describing 37 health conditions were curated and the associations modelled between these and 1-year mortality risk using the Cox proportional hazard model in a development dataset (n = 300 000). Two simplified models were then developed — a 20-condition model as per the original Cambridge Multimorbidity Score and a variable reduction model using backward elimination with Akaike information criterion as the stopping criterion. The results were compared and validated for 1-year mortality in a synchronous validation dataset (n = 150 000), and for 1-year and 5-year mortality in an asynchronous validation dataset (n = 150 000). Results: The final variable reduction model retained 21 conditions, and the conditions mostly overlapped with those in the 20-condition model. The model performed similarly to the 37- and 20-condition models, showing high discrimination and good calibration following recalibration. Conclusion: This modified version of the Cambridge Multimorbidity Score allows reliable estimation using clinical terms that can be applied internationally across multiple healthcare settings. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Heart failure therapy in patients with coronary artery disease
- Author
-
Taylor, Clare J and Hobbs, FD Richard
- Published
- 2013
- Full Text
- View/download PDF
19. Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014-2019).
- Author
-
Joy, Mark, Williams, John, Emanuel, Subo, Kar, Debasish, Xuejuan Fan, Delanerolle, Gayathri, Field, Benjamin C. T., Heiss, Christian, Pollock, Kevin G., Sandler, Belinda, Arora, Jasleen, Sheppard, James P., Feher, Michael, Hobbs, Richard, de Lusignan, Simon, Fan, Xuejuan, Field, Benjamin Ct, and Hobbs, Fd Richard
- Subjects
ORAL medication ,DRUG prescribing ,ANTICOAGULANTS ,PRIMARY care ,ELECTRONOGRAPHY ,ATRIAL fibrillation - Abstract
Background: In England, most prescribing of direct-acting oral anticoagulants for atrial fibrillation (AF) is in primary care. However, there remain gaps in our understanding of dosage and disparities in use. We aimed to describe trends in direct oral anticoagulant (DOAC) prescribing, including dose reduction in people with renal impairment and other criteria, and adherence.Methods: Using English primary care sentinel network data from 2014 to 2019, we assessed appropriate DOAC dose adjustment with creatinine clearance (CrCl). Our primary care sentinel cohort was a subset of 722 general practices, with 6.46 million currently registered patients at the time of this study.Results: Of 6 464 129 people in the cohort, 2.3% were aged ≥18 years with a diagnosis of AF, and 30.8% of these were prescribed vitamin K antagonist and 69.1% DOACs. Appropriate DOAC prescribing following CrCl measures improved between 2014 and 2019; dabigatran from 21.3% (95% CI 15.1% to 28.8%) to 48.7% (95% CI 45.0% to 52.4%); rivaroxaban from 22.1% (95% CI 16.7% to 28.4%) to 49.9% (95% CI 48.5% to 53.3%); edoxaban from 10.0% (95% CI 0.3% to 44.5%) in 2016 to 57.6% (95% CI 54.5% to 60.7%) in 2019; apixaban from 30.8% (95% CI 9.1% to 61.4%) in 2015 to 60.5% (95% CI 57.8% to 63.2%) in 2019.Adherence was highest for factor Xa inhibitors, increasing from 50.1% (95% CI 47.7% to 52.4%) in 2014 to 57.8% (95% CI 57.4% to 58.2%) in 2019. Asian and black/mixed ethnicity was associated with non-adherence (OR 1.81, 95% CI 1.56 to 2.09) as was male gender (OR 1.19, 95% CI 1.15 to 1.22), higher socioeconomic status (OR 1.60, 95% CI 1.52 to 1.68), being an ex-smoker (OR 1.12, 95% CI 1.06 to 1.19) and hypertension (OR 1.07, 95% CI 1.03 to 1.17).Conclusions: The volume and quality of DOAC prescribing has increased yearly. Future interventions to augment quality of anticoagulant management should target disparities in adherence. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
20. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study
- Author
-
Lovibond, Kate, Jowett, Sue, Barton, Pelham, Caulfield, Mark, Heneghan, Carl, Hobbs, FD Richard, Hodgkinson, James, Mant, Jonathan, Martin, Una, Williams, Bryan, Wonderling, David, and McManus, Richard J
- Published
- 2011
- Full Text
- View/download PDF
21. Chronic renal disease is not chronic kidney disease: implications for use of the QRISK and Joint British Societies risk scores
- Author
-
Stevens, Sarah L, Stevens, Richard J, Hobbs, FD Richard, and Lasserson, Daniel S
- Published
- 2016
- Full Text
- View/download PDF
22. Natriuretic peptide testing and heart failure diagnosis in primary care: diagnostic accuracy study.
- Author
-
Taylor, Clare J, Ordóñez-Mena, José M, Lay-Flurrie, Sarah L, Goyder, Clare R, Taylor, Kathryn S, Jones, Nicholas R, Roalfe, Andrea K, and Hobbs, FD Richard
- Subjects
HEART failure ,PEPTIDES ,PRIMARY care ,SECONDARY care (Medicine) ,ALDOSTERONE antagonists ,DIAGNOSIS ,BRAIN natriuretic factor - Abstract
Background: Natriuretic peptide (NP) testing is recommended for patients presenting to primary care with symptoms of chronic heart failure (HF) to prioritise referral for diagnosis. Aim: To report NP test performance at European Society of Cardiology (ESC) and National Institute for Health and Care Excellence (NICE) guideline referral thresholds. Design and setting: Diagnostic accuracy study using linked primary and secondary care data (2004 to 2018). Method: The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of NP testing for HF diagnosis was assessed. Results: In total, 229 580 patients had an NP test and 21 102 (9.2%) were diagnosed with HF within 6 months. The ESC NT-proBNP threshold ≥125 pg/mL had a sensitivity of 94.6% (95% confidence interval [CI] = 94.2 to 95.0) and specificity of 50.0% (95% CI = 49.7 to 50.3), compared with sensitivity of 81.7% (95% CI = 81.0 to 82.3) and specificity of 80.3% (95% CI = 80.0 to 80.5) for the NICE NT-proBNP ≥400 pg/mL threshold. PPVs for an NT-proBNP test were 16.4% (95% CI = 16.1 to 16.6) and 30.0% (95% CI = 29.6 to 30.5) for ESC and NICE thresholds, respectively. For both guidelines, nearly all patients with an NT-proBNP level below the threshold did not have HF (NPV: ESC 98.9%, 95% CI = 98.8 to 99.0 and NICE 97.7%, 95% CI = 97.6 to 97.8). Conclusion: At the higher NICE chronic HF guideline NP thresholds, one in five cases are initially missed in primary care but the lower ESC thresholds require more diagnostic assessments. NP is a reliable 'rule-out' test at both cut-points. The optimal NP threshold will depend on the priorities and capacity of the healthcare system. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial
- Author
-
McManus, Richard J, Mant, Jonathan, Bray, Emma P, Holder, Roger, Jones, Miren I, Greenfield, Sheila, Kaambwa, Billingsley, Banting, Miriam, Bryan, Stirling, Little, Paul, Williams, Bryan, and Hobbs, FD Richard
- Published
- 2010
- Full Text
- View/download PDF
24. Two-year outcomes of UK patients newly diagnosed with atrial fibrillation: findings from the prospective observational cohort study GARFIELD-AF.
- Author
-
Apenteng, Patricia N, Virdone, Saverio, Hobbs, FD Richard, Camm, A John, Fox, Keith AA, Pieper, Karen S, Kayani, Gloria, and Fitzmaurice, David
- Subjects
ATRIAL fibrillation ,COHORT analysis ,TREATMENT effectiveness ,ORAL medication ,SCIENTIFIC observation ,ATRIAL flutter - Abstract
Background: The outcomes of patients newly diagnosed with atrial fibrillation (AF) following the introduction of direct-acting oral anticoagulants are not well known. Aim: To determine the 2-year outcomes of patients newly diagnosed with AF, and the effectiveness of oral anticoagulants in everyday practice. Design and setting: This was a prospective observational cohort study in UK primary care. Method: In total, 3574 patients aged ≥18 years with a new AF diagnosis were enrolled. A propensity score was applied using an overlap weighting scheme to obtain unbiased estimates of the treatment effect of anticoagulation versus no anticoagulation on the occurrence of death, non-haemorrhagic stroke/systemic embolism, and major bleeding within 2 years of diagnosis. Results: Overall, 65.8% received anticoagulant therapy, 20.8% received an antiplatelet only, and 13.4% received neither. During the study period, the overall incidence rates of all-cause mortality, non-haemorrhagic stroke/systemic embolism, and major bleeding were 4.15 (95% confidence interval [CI] = 3.69 to 4.65), 1.45 (95% CI = 1.19 to 1.77), and 1.21 (95% CI = 0.97 to 1.50) per 100 person–years, respectively. Anticoagulation treatment compared with no anticoagulation treatment was associated with significantly lower all-cause mortality adjusted hazard ratio (aHR) 0.70 (95% CI = 0.53 to 0.93), significantly lower risk of non-haemorrhagic stroke/systemic embolism (aHR 0.39, 95% CI = 0.24 to 0.62), and a non-significant higher risk of major bleeding (aHR 1.31, 95% CI = 0.77 to 2.24). Conclusion: The data support a benefit of anticoagulation in reducing stroke and death, without an increased risk of a major bleed in patients with new-onset AF. Anticoagulation treatment in patients at high risk of stroke who are not receiving anticoagulation may further improve outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Commentary: Last and Icebergs – spotting the iceberg doesn’t predict its scale, even after 50 years
- Author
-
Hobbs, FD Richard
- Published
- 2013
- Full Text
- View/download PDF
26. Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial
- Author
-
Hill, Nathan R, Lasserson, Daniel, Thompson, Ben, Perera-Salazar, Rafael, Wolstenholme, Jane, Bower, Peter, Blakeman, Thomas, Fitzmaurice, David, Little, Paul, Feder, Gene, Qureshi, Nadeem, Taal, Maarten, Townend, Jonathan, Ferro, Charles, McManus, Richard, and Hobbs, FD Richard
- Published
- 2014
- Full Text
- View/download PDF
27. A cross-sectional study of hypertension in an elderly population (75 years and over) with atrial fibrillation: Secondary analysis of data from the Birmingham Atrial Fibrillation in the Aged (BAFTA) randomised controlled trial
- Author
-
Hurley, Victoria, Ireson, Rosa, Fletcher, Kate, Lip, Gregory YH, Hobbs, FD Richard, and Mant, Jonathan
- Published
- 2007
- Full Text
- View/download PDF
28. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
- Author
-
Mant, Jonathan, Hobbs, FD Richard, Fletcher, Kate, Roalfe, Andrea, Fitzmaurice, David, Lip, Gregory YH, and Murray, Ellen
- Published
- 2007
- Full Text
- View/download PDF
29. Natriuretic peptide level at heart failure diagnosis and risk of hospitalisation and death in England 2004-2018.
- Author
-
Taylor, Clare J., Lay-Flurrie, Sarah L., Ordóñez-Mena, José M., Goyder, Clare R., Jones, Nicholas R., Roalfe, Andrea K., Richard Hobbs, F. D., and Hobbs, Fd Richard
- Subjects
HEART failure ,PEPTIDES ,MORTALITY ,NURSE practitioners ,MUSCULOSKELETAL system diseases ,DIGESTIVE system diseases ,DIAGNOSIS - Abstract
Objective: Heart failure (HF) is a malignant condition requiring urgent treatment. Guidelines recommend natriuretic peptide (NP) testing in primary care to prioritise referral for specialist diagnostic assessment. We aimed to assess association of baseline NP with hospitalisation and mortality in people with newly diagnosed HF.Methods: Population-based cohort study of 40 007 patients in the Clinical Practice Research Datalink in England with a new HF diagnosis (48% men, mean age 78.5 years). We used linked primary and secondary care data between 1 January 2004 and 31 December 2018 to report one-year hospitalisation and 1-year, 5-year and 10-year mortality by NP level.Results: 22 085 (55%) participants were hospitalised in the year following diagnosis. Adjusted odds of HF-related hospitalisation in those with a high NP (NT-proBNP >2000 pg/mL) were twofold greater (OR 2.26 95% CI 1.98 to 2.59) than a moderate NP (NT-proBNP 400-2000 pg/mL). All-cause mortality rates in the high NP group were 27%, 62% and 82% at 1, 5 and 10 years, compared with 19%, 50% and 77%, respectively, in the moderate NP group and, in a competing risks model, risk of HF-related death was 50% higher at each timepoint. Median time between NP test and HF diagnosis was 101 days (IQR 19-581).Conclusions: High baseline NP is associated with increased HF-related hospitalisation and poor survival. While healthcare systems remain under pressure from the impact of COVID-19, research to test novel strategies to prevent hospitalisation and improve outcomes-such as a mandatory two-week HF diagnosis pathway-is urgently needed. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
30. Change in glomerular filtration rate over time in the Oxford Renal Cohort Study: observational study.
- Author
-
Hirst, Jennifer A, Taal, Maarten W, Fraser, Simon Ds, Mena, José M Ordóñez, O'Callaghan, Chris A, McManus, Richard J, Taylor, Clare J, Yang, Yaling, Ogburn, Emma, and Hobbs, Fd Richard
- Subjects
GLOMERULAR filtration rate ,PROPORTIONAL hazards models ,SYSTOLIC blood pressure ,COHORT analysis ,CHRONIC kidney failure ,DISEASE progression ,KIDNEYS ,LONGITUDINAL method - Abstract
Background: Decline in kidney function can result in adverse health outcomes. The Oxford Renal Cohort Study has detailed baseline assessments from 884 participants ≥60 years of age.Aim: To determine the proportion of participants with a decline in estimated glomerular filtration rate (eGFR), identify determinants of decline, and determine proportions with chronic kidney disease (CKD) remission.Design and Setting: Observational cohort study in UK primary care.Method: Data were used from baseline and annual follow-up assessments to monitor change in kidney function. Rapid eGFR decline was defined as eGFR decrease >5 ml/min/1.73 m2/year, improvement as eGFR increase >5 ml/min/1.73 m2/year, and remission in those with CKD at baseline and eGFR >60 ml/min/1.73 m2 during follow-up. Cox proportional hazard models were used to identify factors associated with eGFR decline.Results: There was a net decline in eGFR in the 884 participants over 5 years of follow-up. In 686 participants with >2 eGFR tests with a median follow-up of 2.1 years, 164 (24%) evidenced rapid GFR decline, 185 (27%) experienced eGFR improvement, and 82 of 394 (21%) meeting CKD stage 1-4 at baseline experienced remission. In the multivariable analysis, smoking status, higher systolic blood pressure, and being known to have CKD at cohort entry were associated with rapid GFR decline. Those with CKD stage 3 at baseline were less likely to exhibit GFR decline compared with normal kidney function.Conclusion: This study established that 24% of people evidenced rapid GFR decline whereas 21% evidenced remission of CKD. People at risk of rapid GFR decline may benefit from closer monitoring and appropriate treatment to minimise risks of adverse outcomes, although only a small proportion meet the National Institute for Health and Care Excellence criteria for referral to secondary care. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
31. Primary prevention of ischaemic heart disease
- Author
-
Hobbs, FD Richard
- Published
- 2006
- Full Text
- View/download PDF
32. Reducing cardiovascular risk in diabetes: Beyond glycemic and blood pressure control
- Author
-
Hobbs, FD Richard
- Published
- 2006
- Full Text
- View/download PDF
33. Exploring weight loss services in primary care and staff views on using a web-based programme
- Author
-
Ware, Lisa J, Williams, Sarah, Bradbury, Katherine, Brant, Catherine, Little, Paul, Hobbs, FD Richard, and Yardley, Lucy
- Published
- 2012
34. The Authorsʼ reply
- Author
-
Hobbs, FD Richard, Doust, Jenny, Mant, Jonathan, and Cowie, Martin R
- Published
- 2011
- Full Text
- View/download PDF
35. Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial)
- Author
-
Delaney, Brendan C, Qume, Michelle, Moayyedi, Paul, Logan, Richard F A, Ford, Alexander C, Elliott, Cathy, McNulty, Cliodna, Wilson, Sue, and Hobbs, FD Richard
- Published
- 2008
36. How representative of primary care are research active practices? Cross-sectional survey
- Author
-
McManus, Richard J, Ryan, Ronan, Jones, Miren, Wilson, Sue, and Hobbs, FD Richard
- Published
- 2008
37. An analysis of factors that predict patient consent to take part in a randomized controlled trial
- Author
-
Fletcher, Kate, Mant, Jonathan, Holder, Roger, Fitzmaurice, David, Lip, Gregory YH, and Hobbs, FD Richard
- Published
- 2007
38. Concordance with heart failure medications: what do patients think?
- Author
-
Hobbs, FD Richard
- Published
- 2006
39. Frequency of Renal Monitoring - Creatinine and Cystatin C (FORM-2C): an observational cohort study of patients with reduced eGFR in primary care.
- Author
-
Fleming, Susannah, Perera-Salazar, Rafael, Taylor, Kathryn S, Jones, Louise, Hobbs, FD Richard, James, Tim, O'Callaghan, Chris A, Shine, Brian, Verbakel, Jan Y, Stevens, Richard, and Bankhead, Clare
- Subjects
CYSTATIN C ,EPIDERMAL growth factor receptors ,PRIMARY care ,CREATININE ,GLOMERULAR filtration rate ,KIDNEY physiology ,PROTEINS ,RESEARCH ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,PRIMARY health care ,COMPARATIVE studies ,LONGITUDINAL method - Abstract
Background: Monitoring is the mainstay of chronic kidney disease management in primary care; however, there is little evidence about the best way to do this.Aim: To compare the effectiveness of estimated glomerular filtration rate (eGFR) derived from serum creatinine and serum cystatin C to predict renal function decline among those with a recent eGFR of 30-89 ml/min/1.73 m2.Design and Setting: Observational cohort study in UK primary care.Method: Serum creatinine and serum cystatin C were both measured at seven study visits over 2 years in 750 patients aged ≥18 years with an eGFR of 30-89 ml/min/1.73 m2 within the previous year. The primary outcome was change in eGFR derived from serum creatinine or serum cystatin C between 6 and 24 months.Results: Average change in eGFR was 0.51 ml/min/1.73 m2/year when estimated by serum creatinine and -2.35 ml/min/1.73 m2/year when estimated by serum cystatin C. The c-statistic for predicting renal decline using serum creatininederived eGFR was 0.495 (95% confidence interval [CI] = 0.471 to 0.519). The equivalent c-statistic using serum cystatin C-derived eGFR was 0.497 (95% CI = 0.468 to 0.525). Similar results were obtained when restricting analyses to those aged ≥75 or <75 years, or with eGFR ≥60 ml/min/1.73 m2. In those with eGFR <60 ml/min/1.73 m2, serum cystatin C-derived eGFR was more predictive than serum creatinine-derived eGFR for future decline in kidney function.Conclusion: In the primary analysis neither eGFR estimated from serum creatinine nor from serum cystatin C predicted future change in kidney function, partly due to small changes during 2 years. In some secondary analyses there was a suggestion that serum cystatin C was a more useful biomarker to estimate eGFR, especially in those with a baseline eGFR <60 ml/min/1.73 m2. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
40. Survival of people with valvular heart disease in a large, English community-based cohort study.
- Author
-
Taylor, Clare J., Ordóñez-Mena, José M., Jones, Nicholas R., Roalfe, Andrea K., Myerson, Saul G., Prendergast, Bernard D., Hobbs, F. D. Richard, and Hobbs, Fd Richard
- Subjects
HEART valve diseases ,COHORT analysis ,AORTA ,MORTALITY ,CLINICAL trial registries ,OLDER patients ,ECHOCARDIOGRAPHY ,CAUSES of death ,RESEARCH ,RESEARCH methodology ,ACQUISITION of data ,PROGNOSIS ,MEDICAL cooperation ,EVALUATION research ,SEVERITY of illness index ,RISK assessment ,COMPARATIVE studies ,DISEASE prevalence ,SURVIVAL analysis (Biometry) ,RESEARCH funding - Abstract
Objective: Valvular heart disease (VHD) is present in half the population aged >65 years but is usually mild and of uncertain importance. We investigated the association between VHD and its phenotypes with all-cause and cause-specific mortality.Methods: The OxVALVE (Oxford Valvular Heart Disease) population cohort study screened 4009 participants aged >65 years to establish the presence and severity of VHD. We linked data to a national mortality registry and undertook detailed outcome analysis.Results: Mortality data were available for 3511 participants, of whom 361 (10.3%) died (median 6.49 years follow-up). Most had some form of valve abnormality (n=2645, 70.2%). In adjusted analyses, neither mild VHD (prevalence 44.9%) nor clinically significant VHD (moderate or severe stenosis or regurgitation; 5.2%) was associated with increased all-cause mortality (HR 1.20, 95% CI 0.96 to 1.51 and HR 1.47, 95% CI 0.94 to 2.31, respectively). Conversely, advanced aortic sclerosis (prevalence 2.25%) and advanced mitral annular calcification (MAC, 1.31%) were associated with an increased risk of death (HR 2.05, 95% CI 1.28 to 3.30 and HR 2.51, 95% CI 1.41 to 4.49, respectively). Mortality was highest for people with both clinically significant VHD and advanced aortic sclerosis or MAC (HR 4.38, 95% CI 1.99 to 9.67).Conclusions: Advanced aortic sclerosis or MAC is associated with a worse outcome, particularly for patients with significant VHD, but also in the absence of other VHD. Older patients with mild VHD can be reassured about their prognosis. The absence of an association between significant VHD and mortality may reflect its relatively low prevalence in our cohort. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
41. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey
- Author
-
Hobbs, FD Richard and Erhardt, Leif
- Published
- 2002
42. ‘I’ and ‘we’: a concordancing analysis of how doctors and patients use first person pronouns in primary care consultations
- Author
-
Skelton, John R, Wearn, Andy M, and Hobbs, FD Richard
- Published
- 2002
43. Measuring the complexity of general practice consultations: a Delphi and cross-sectional study in English primary care.
- Author
-
Salisbury, Chris, Lay-Flurrie, Sarah, Bankhead, Clare R, Fuller, Alice, Murphy, Mairead, Caddick, Barbara, Ordóñez-Mena, José M, Holt, Tim, Nicholson, Brian D, Perera, Rafael, and Hobbs, FD Richard
- Subjects
PRIMARY care ,CROSS-sectional method ,DELPHI method ,REGRESSION analysis ,MEDICAL research - Abstract
Background: The complexity of general practice consultations may be increasing and varies in different settings. A measure of complexity is required to test these hypotheses.Aim: To develop a valid measure of general practice consultation complexity applicable to routine medical records.Design and Setting: Delphi study to select potential indicators of complexity followed by a cross-sectional study in English general practices to develop and validate a complexity measure.Method: The online Delphi study over two rounds identified potential indicators of consultation complexity. The cross-sectional study used an age-sex stratified random sample of patients and general practice face-to-face consultations from 2013/2014 in the Clinical Practice Research Datalink. The authors explored independent relationships between each indicator and consultation duration using mixed-effects regression models, and revalidated findings using data from 2017/2018. The proportion of complex consultations in different age-sex groups was assessed.Results: A total of 32 GPs participated in the Delphi study. The Delphi panel endorsed 34 of 45 possible complexity indicators after two rounds. After excluding factors because of low prevalence or confounding, 17 indicators were retained in the cross-sectional study. The study used data from 173 130 patients and 725 616 face-to-face GP consultations. On defining complexity as the presence of any of these 17 factors, 308 370 consultations (42.5%) were found to be complex. Mean duration of complex consultations was 10.49 minutes, compared to 9.64 minutes for non-complex consultations. The proportion of complex consultations was similar in males and females but increased with age.Conclusion: The present consultation complexity measure has face and construct validity. It may be useful for research, management and policy, and for informing decisions about the range of resources needed in different practices. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
44. GPs' use of gut feelings when assessing cancer risk: a qualitative study in UK primary care.
- Author
-
Smith, Claire Friedemann, Kristensen, Benedikte Møller, Andersen, Rikke Sand, Hobbs, FD Richard, Ziebland, Sue, and Nicholson, Brian D
- Subjects
PRIMARY care ,QUALITATIVE research ,DECISION making ,EMOTIONS ,RISK assessment - Abstract
Background: The use of gut feelings to guide clinical decision making in primary care has been frequently described but is not considered a legitimate reason for cancer referral.Aim: To explore the role that gut feeling plays in clinical decision making in primary care.Design and Setting: Qualitative interview study with 19 GPs in Oxfordshire, UK.Method: GPs who had referred patients to a cancer pathway based on a gut feeling as a referral criterion were invited to participate. Interviews were conducted between November 2019 and January 2020, and transcripts were analysed using the one sheet of paper method.Results: Gut feeling was seen as an essential part of decision making that facilitated appropriate and timely care. GPs distanced their gut feelings from descriptions that could be seen as unscientific, describing successful use as reliant on experience and clinical knowledge. This was especially true for patients who fell within a 'grey area' where clinical guidelines did not match the GP's assessment of cancer risk, either because the guidance inadequately represented or did not include the patient's presentation. GPs sought to legitimise their gut feelings by gathering objective clinical evidence, careful examination of referral procedures, and consultation with colleagues.Conclusion: GPs described their gut feelings as important to decision making in primary care and a necessary addition to clinical guidance. The steps taken to legitimise their gut feelings matched that expected in good clinical practice. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
45. Clinical prediction tools to identify patients at highest risk of myeloma in primary care: a retrospective open cohort study.
- Author
-
Koshiaris, Constantinos, Van den Bruel, Ann, Nicholson, Brian D, Lay-Flurrie, Sarah, Hobbs, FD Richard, and Oke, Jason L
- Subjects
RIB fractures ,BLOOD cell count ,PRIMARY care ,CHEST pain ,BLOOD sedimentation ,PROPORTIONAL hazards models ,CLINICAL prediction rules - Abstract
Background: Patients with myeloma experience substantial delays in their diagnosis, which can adversely affect their prognosis.Aim: To generate a clinical prediction rule to identify primary care patients who are at highest risk of myeloma.Design and Setting: Retrospective open cohort study using electronic health records data from the UK's Clinical Practice Research Datalink (CPRD) between 1 January 2000 and 1 January 2014.Method: Patients from the CPRD were included in the study if they were aged ≥40 years, had two full blood counts within a year, and had no previous diagnosis of myeloma. Cases of myeloma were identified in the following 2 years. Derivation and external validation datasets were created based on geographical region. Prediction equations were estimated using Cox proportional hazards models including patient characteristics, symptoms, and blood test results. Calibration, discrimination, and clinical utility were evaluated in the validation set.Results: Of 1 281 926 eligible patients, 737 (0.06%) were diagnosed with myeloma within 2 years. Independent predictors of myeloma included: older age; male sex; back, chest and rib pain; nosebleeds; low haemoglobin, platelets, and white cell count; and raised mean corpuscular volume, calcium, and erythrocyte sedimentation rate. A model including symptoms and full blood count had an area under the curve of 0.84 (95% CI = 0.81 to 0.87) and sensitivity of 62% (95% CI = 55% to 68%) at the highest risk decile. The corresponding statistics for a second model, which also included calcium and inflammatory markers, were an area under the curve of 0.87 (95% CI = 0.84 to 0.90) and sensitivity of 72% (95% CI = 66% to 78%).Conclusion: The implementation of these prediction rules would highlight the possibility of myeloma in patients where GPs do not suspect myeloma. Future research should focus on the prospective evaluation of further external validity and the impact on clinical practice. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
46. Impact of changes to national guidelines on hypertension-related workload: an interrupted time series analysis in English primary care.
- Author
-
Lay-Flurrie, Sarah L, Sheppard, James P, Stevens, Richard J, Mallen, Christian, Heneghan, Carl, Hobbs, FD Richard, Williams, Bryan, Mant, Jonathan, and McManus, Richard J
- Subjects
TIME series analysis ,PRIMARY care ,BLOOD pressure ,HYPERTENSION ,DIAGNOSIS ,HELPLINES ,HYPERTENSION epidemiology ,RETROSPECTIVE studies ,PRIMARY health care ,EMPLOYEES' workload ,IMPACT of Event Scale ,LONGITUDINAL method - Abstract
Background: In 2011, National Institute for Health and Care Excellence (NICE) guidelines recommended the routine use of out-of-office blood pressure (BP) monitoring for the diagnosis of hypertension. These changes were predicted to reduce unnecessary treatment costs and workload associated with misdiagnosis.Aim: To assess the impact of guideline change on rates of hypertension-related consultation in general practice.Design and Setting: A retrospective open cohort study in adults registered with English general practices contributing to the Clinical Practice Research Datalink between 1 April 2006 and 31 March 2017.Method: The primary outcome was the rate of face-to-face, telephone, and home visit consultations related to hypertension with a GP or nurse. Age- and sex-standardised rates were analysed using interrupted time-series analysis.Results: In 3 937 191 adults (median follow-up 4.2 years) there were 12 253 836 hypertension-related consultations. The rate of hypertension-related consultation was 71.0 per 100 person-years (95% confidence interval [CI] = 67.8 to 74.2) in April 2006, which remained flat before 2011. The introduction of the NICE hypertension guideline in 2011 was associated with a change in yearly trend (change in trend -3.60 per 100 person-years, 95% CI = -5.12 to -2.09). The rate of consultation subsequently decreased to 59.2 per 100 person-years (95% CI = 56.5 to 61.8) in March 2017. These changes occurred around the time of diagnosis, and persisted when accounting for wider trends in all consultations.Conclusion: Hypertension-related workload has declined in the last decade, in association with guideline changes. This is due to changes in workload at the time of diagnosis, rather than reductions in misdiagnosis. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
47. Are more GPs associated with a reduction in emergency hospital admissions? A quantitative study on GP referral in England.
- Author
-
Nicodemo, Catia, McCormick, Barry, Wittenberg, Raphael, and Hobbs, FD Richard
- Subjects
QUANTITATIVE research ,HOSPITAL admission & discharge ,HOSPITAL statistics ,REGRESSION analysis ,PANEL analysis ,HOSPITALS ,HOSPITAL emergency services ,MEDICAL referrals ,HOSPITAL care - Abstract
Background: Recent studies have found an association between access to primary care and accident and emergency attendances, with better access associated with fewer attendances. Analyses of an association with emergency admissions, however, have produced conflicting findings.Aim: This study investigated whether emergency admission rates in an area are associated with 1) the number of GPs, and 2) mean size of GP practice.Design and Setting: Analysis was conducted utilising Hospital Episode Statistics, the numbers of GPs and GP practices, Office for National Statistics population data, Quality and Outcomes Framework prevalence data, and Index of Multiple Deprivation data, from 2004/2005 to 2011/2012, for all practices in England.Method: Regression analysis of panel data with fixed effects to address 1) a potential two-way relationship between the numbers of GPs and emergency admissions, and 2) unobservable characteristics of GP practices.Results: There is not a statistically significant relationship between the number of GPs in a primary care trust area and the number of emergency admissions, when analysing all areas. In deprived areas, however, a higher number of GPs is associated with lower emergency admissions. There is also a lower emergency admission rate in areas in which practices are on average larger, holding GP supply constant.Conclusion: An increase in GPs was found to reduce emergency admissions in deprived areas, but not elsewhere. Areas in which GPs are concentrated into larger practices showed reduced levels of emergency admissions, all else being equal. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
48. Excess mortality in the first COVID pandemic peak: cross-sectional analyses of the impact of age, sex, ethnicity, household size, and long-term conditions in people of known SARS-CoV-2 status in England.
- Author
-
Joy, Mark, Hobbs, FD Richard, Bernal, Jamie Lopez, Sherlock, Julian, Amirthalingam, Gayatri, McGagh, Dylan, Akinyemi, Oluwafunmi, Byford, Rachel, Dabrera, Gavin, Dorward, Jienchi, Ellis, Joanna, Ferreira, Filipa, Jones, Nicholas, Oke, Jason, Okusi, Cecilia, Nicholson, Brian D, Ramsay, Mary, Sheppard, James P, Sinnathamby, Mary, and Zambon, Maria
- Subjects
COVID-19 pandemic ,SARS-CoV-2 ,CROSS-sectional method ,PEOPLE with learning disabilities ,SURVIVAL analysis (Biometry) - Abstract
Background: The SARS-CoV-2 pandemic has passed its first peak in Europe.Aim: To describe the mortality in England and its association with SARS-CoV-2 status and other demographic and risk factors.Design and Setting: Cross-sectional analyses of people with known SARS-CoV-2 status in the Oxford RCGP Research and Surveillance Centre (RSC) sentinel network.Method: Pseudonymised, coded clinical data were uploaded from volunteer general practice members of this nationally representative network (n = 4 413 734). All-cause mortality was compared with national rates for 2019, using a relative survival model, reporting relative hazard ratios (RHR), and 95% confidence intervals (CI). A multivariable adjusted odds ratios (OR) analysis was conducted for those with known SARS-CoV-2 status (n = 56 628, 1.3%) including multiple imputation and inverse probability analysis, and a complete cases sensitivity analysis.Results: Mortality peaked in week 16. People living in households of ≥9 had a fivefold increase in relative mortality (RHR = 5.1, 95% CI = 4.87 to 5.31, P<0.0001). The ORs of mortality were 8.9 (95% CI = 6.7 to 11.8, P<0.0001) and 9.7 (95% CI = 7.1 to 13.2, P<0.0001) for virologically and clinically diagnosed cases respectively, using people with negative tests as reference. The adjusted mortality for the virologically confirmed group was 18.1% (95% CI = 17.6 to 18.7). Male sex, population density, black ethnicity (compared to white), and people with long-term conditions, including learning disability (OR = 1.96, 95% CI = 1.22 to 3.18, P = 0.0056) had higher odds of mortality.Conclusion: The first SARS-CoV-2 peak in England has been associated with excess mortality. Planning for subsequent peaks needs to better manage risk in males, those of black ethnicity, older people, people with learning disabilities, and people who live in multi-occupancy dwellings. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
49. Reorganisation of primary care for older adults during COVID-19: a cross-sectional database study in the UK.
- Author
-
Joy, Mark, McGagh, Dylan, Jones, Nicholas, Liyanage, Harshana, Sherlock, Julian, Parimalanathan, Vaishnavi, Akinyemi, Oluwafunmi, van Vlymen, Jeremy, Howsam, Gary, Marshall, Martin, Hobbs, FD Richard, and de Lusignan, Simon
- Subjects
COVID-19 ,OLDER people ,PRIMARY care ,COVID-19 pandemic ,CROSS-sectional method ,HOME care service statistics ,CORONAVIRUS disease treatment ,VIRAL pneumonia ,PRIMARY health care ,EPIDEMICS - Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has resulted in a rapid change in workload across healthcare systems. Factors related to this adaptation in UK primary care have not yet been examined.Aim: To assess the responsiveness and prioritisation of primary care consultation type for older adults during the COVID-19 pandemic.Design and Setting: A cross-sectional database study examining consultations between 17 February and 10 May 2020 for patients aged ≥65 years, drawn from primary care practices within the Oxford Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) sentinel network, UK.Method: The authors reported the proportion of consultation type across five categories: clinical administration, electronic/video, face-to-face, telephone, and home visits. Temporal trends in telephone and face-to-face consultations were analysed by polypharmacy, frailty status, and socioeconomic group using incidence rate ratios (IRR).Results: Across 3 851 304 consultations, the population median age was 75 years (interquartile range [IQR] 70-82); and 46% (n = 82 926) of the cohort (N = 180 420) were male. The rate of telephone and electronic/video consultations more than doubled across the study period (106.0% and 102.8%, respectively). Face-to-face consultations fell by 64.6% and home visits by 62.6%. This predominantly occurred across week 11 (week commencing 9 March 2020), coinciding with national policy change. Polypharmacy and frailty were associated with a relative increase in consultations. The greatest relative increase was among people taking ≥10 medications compared with those taking none (face-to-face IRR 9.90, 95% CI = 9.55 to 10.26; telephone IRR 17.64, 95% CI = 16.89 to 18.41).Conclusion: Primary care has undergone an unprecedented in-pandemic reorganisation while retaining focus on patients with increased complexity. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
50. Accuracy of blood-pressure monitors owned by patients with hypertension (ACCU-RATE study): a cross-sectional, observational study in central England.
- Author
-
Hodgkinson, James A, Lee, Mei-Man, Milner, Siobhan, Bradburn, Peter, Stevens, Richard, Hobbs, FD Richard, Koshiaris, Constantinos, Grant, Sabrina, Mant, Jonathan, and McManus, Richard J
- Subjects
BLOOD pressure testing machines ,MEDICAL personnel as patients ,STATIC pressure ,PATIENT monitoring ,SCIENTIFIC observation ,HYPERTENSION ,HYPERTENSION epidemiology ,BLOOD pressure ,RESEARCH ,CROSS-sectional method ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,PSYCHOLOGICAL tests ,SPHYGMOMANOMETERS ,AMBULATORY blood pressure monitoring ,BLOOD pressure measurement - Abstract
Background: Home blood-pressure (BP) monitoring is recommended in guidelines and is increasingly popular with patients and health professionals, but the accuracy of patients' own monitors in real-world use is not known.Aim: To assess the accuracy of home BP monitors used by people with hypertension, and to investigate factors affecting accuracy.Design and Setting: Cross-sectional, observational study in urban and suburban settings in central England.Method: Patients (n = 6891) on the hypertension register at seven practices in the West Midlands, England, were surveyed to ascertain whether they owned a BP monitor and wanted it tested. Monitor accuracy was compared with a calibrated reference device at 50 mmHg intervals between 0-280/300 mmHg (static pressure test); a difference from the reference monitor of +/-3 mmHg at any interval was considered a failure. Cuff performance was also assessed. Results were analysed by frequency of use, length of time in service, make and model, monitor validation status, purchase price, and any previous testing.Results: In total, 251 (76%, 95% confidence interval [95% CI] = 71 to 80%) of 331 tested devices passed all tests (monitors and cuffs), and 86% (CI] = 82 to 90%) passed the static pressure test; deficiencies were, primarily, because of monitors overestimating BP. A total of 40% of testable monitors were not validated. The pass rate on the static pressure test was greater in validated monitors (96%, 95% CI = 94 to 98%) versus unvalidated monitors (64%, 95% CI = 58 to 69%), those retailing for >£10 (90%, 95% CI = 86 to 94%), those retailing for ≤£10 (66%, 95% CI = 51 to 80%), those in use for ≤4 years (95%, 95% CI = 91 to 98%), and those in use for >4 years (74%, 95% CI = 67 to 82%). All in all, 12% of cuffs failed.Conclusion: Patients' own BP monitor failure rate was similar to that demonstrated in studies performed in professional settings, although cuff failure was more frequent. Clinicians can be confident of the accuracy of patients' own BP monitors if the devices are validated and ≤4 years old. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.